Cargando…

Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma

PURPOSE: Sorafenib is the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), and its clinical response rate is only about 10%. In clinical practice, some HCC patients obtain favorable overall survival (OS) to the treatment of sorafenib while some patients do not demo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Zhenfeng, Xu, Litao, Zhuang, Liping, Ning, Zhouyu, Zhang, Chenyue, Yan, Xia, Lin, Junhua, Shen, Yehua, Wang, Peng, Meng, Zhiqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188073/ https://www.ncbi.nlm.nih.gov/pubmed/30349306 http://dx.doi.org/10.2147/OTT.S173275

Ejemplares similares

High-intensity focused ultrasound enhances the effect of bufalin by inducing apoptosis in pancreatic cancer cells
por: Ning, Zhouyu, et al.
Publicado: (2019)

Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients
por: Xu, Litao, et al.
Publicado: (2017)

Prognostic nutritional index serves as a predictive marker of survival and associates with systemic inflammatory response in metastatic intrahepatic cholangiocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2016)

Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2017)

Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway
por: Wang, Haiyong, et al.
Publicado: (2016)

Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy
por: Zhu, Zhen-Feng, et al.
Publicado: (2022)

HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients
por: Ning, Zhouyu, et al.
Publicado: (2019)

ARHGAP4 mediates the Warburg effect in pancreatic cancer through the mTOR and HIF-1α signaling pathways
por: Shen, Yehua, et al.
Publicado: (2019)

Na(+)/K(+)-ATPase α1 subunit, a novel therapeutic target for hepatocellular carcinoma
por: Zhuang, Liping, et al.
Publicado: (2015)

Overexpression of a Long Non-Coding RNA BC037916 is Associated with Pancreatic Tumorigenesis and Poor Prognosis
por: Chen, Gang, et al.
Publicado: (2021)

Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib
por: Lué, Alberto, et al.
Publicado: (2017)

Identification of the prognostic value of lymphocyte-to-monocyte ratio in patients with HBV-associated advanced hepatocellular carcinoma
por: Hong, Ying-Fen, et al.
Publicado: (2017)

Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins
por: Wang, Haiyong, et al.
Publicado: (2018)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2021)

Prognostic significance of lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization and radiofrequency ablation
por: Shen, Yanjun, et al.
Publicado: (2019)

Serum miR-128-2 Serves as a Prognostic Marker for Patients with Hepatocellular Carcinoma
por: Zhuang, Liping, et al.
Publicado: (2015)

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2021)

A monocyte/granulocyte to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma
por: Zhou, Dongsheng, et al.
Publicado: (2015)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in different etiological causes of thyrotoxicosis
por: TAŞKALDIRAN, Işılay, et al.
Publicado: (2019)

Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19
por: Seyit, Murat, et al.
Publicado: (2021)

Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19
por: Seyit, Murat, et al.
Publicado: (2021)

The prognostic impact of neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio in patients with advanced colorectal cancer treated with first-line chemotherapy
por: Krakowska, Magdalena, et al.
Publicado: (2018)

Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma
por: Shi, Lihui, et al.
Publicado: (2016)

Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study
por: Chen, Qiwen, et al.
Publicado: (2016)

Prognostic Significance of Neutrophil to Lymphocyte Ratio, Lymphocyte to Monocyte Ratio, and Platelet to Lymphocyte Ratio in Patients with Nasopharyngeal Carcinoma
por: Lu, Aiying, et al.
Publicado: (2017)

Diagnostic and prognostic role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio in patients with osteosarcoma
por: Yapar, Aliekber, et al.
Publicado: (2021)

Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy
por: Li, Ke-Jie, et al.
Publicado: (2019)

Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte and Monocyte-to-Lymphocyte Ratio in Bipolar Disorder
por: Fusar-Poli, Laura, et al.
Publicado: (2021)

Prognostic significance of lymphocyte monocyte ratio in patients with ovarian cancer
por: Cai, Linrui, et al.
Publicado: (2020)

Prognostic Role of Lymphocyte/Monocyte Ratio in Chronic Lymphocytic Leukemia
por: Yokus, Osman, et al.
Publicado: (2020)

Clinical and prognostic significance of preoperative lymphocyte-monocyte ratio, neutrophil-lymphocyte ratio and neutrophil-monocyte ratio on esophageal squamous cell carcinoma patients
por: Shang, Qi-Xin, et al.
Publicado: (2020)

A Prospective Study on the Roles of the Lymphocyte-to-Monocyte Ratio (LMR), Neutrophil-to-Lymphocyte Ratio (NLR), and Platelet-to-Lymphocyte Ratio (PLR) in Patients with Locally Advanced Rectal Cancer
por: Gawiński, Cieszymierz, et al.
Publicado: (2023)

Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio predict length of hospital stay in myocarditis
por: Mirna, Moritz, et al.
Publicado: (2021)

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
por: Hsu, Chih-Hung, et al.
Publicado: (2014)

Monocyte-to-High-Density Lipoprotein Cholesterol Ratio Together With the Lymphocyte-to-Monocyte Ratio in Predicting the Malignancy of the Thyroid Nodule in Patients Complicated With Type 2 Diabetes
por: Hu, Yingying, et al.
Publicado: (2023)

Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Monocyte-to-Lymphocyte Ratio in Depression: An Updated Systematic Review and Meta-Analysis
por: Cheng, Yanwei, et al.
Publicado: (2022)

Impact on the survival of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and monocyte-lymphocyte ratio on prognosis in children with Hodgkin lymphoma
por: Ertan, Kubra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s2h3h9v32f6q8v6h06m30phnta